1
|
Bordet R, Dantonel JC, Vacaresse E, Le Jeunne C, Benhabiles N, Beretz A, Boitard C, Debette S, Duluc G, Froguel P, Garbil B, Lyonnet S, Mahfoudi A, Marquet P, Mouthon F, Rascol O, Richard V, Simon E, Varoqueaux N, Watier H, Zins M. How has the future investment program stimulated research and innovation in health? Therapie 2022; 77:19-24. [DOI: 10.1016/j.therap.2022.01.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Accepted: 01/07/2022] [Indexed: 10/19/2022]
|
2
|
Bordet R, Dantonel JC, Vacaresse E, Le Jeunne C, Benhabiles N, Beretz A, Boitard C, Debette S, Duluc G, Froguel P, Garbil B, Lyonnet S, Mahfoudi A, Marquet P, Mouthon F, Rascol O, Richard V, Simon E, Varoqueaux N, Watier H, Zins M. Comment le programme d’investissements d’avenir a-t-il stimulé la recherche et l’innovation en santé ? Therapie 2022; 77:11-17. [DOI: 10.1016/j.therap.2022.01.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Accepted: 01/07/2022] [Indexed: 11/17/2022]
|
3
|
Lirsac PN, Blin O, Magalon J, Angot P, de Barbeyrac E, Bilbault P, Bourg E, Damour O, Faure P, Ferry N, Garbil B, Larghero J, Nguon M, Pattou F, Thumelin S, Yates F. Creating conditions for the success of the French industrial advanced therapy sector. Therapie 2015; 70:69-94. [PMID: 25747840 DOI: 10.2515/therapie/2015005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 11/24/2014] [Indexed: 11/20/2022]
Abstract
Although the European Union merely followed the initiatives of the United States and Japan by introducing special regimes for orphan medicinal products, it has introduced a special status for a new category of biological medicinal products, advanced therapy medicinal products (ATMPs), adopting specific associated regulations. European Regulation (which constitutes the highest legal instrument in the hierarchy of European law texts) [EC] No. 1394/2007, published in 2007, uses this term to define somatic cell therapy medicinal products, tissue-engineered products, and gene therapy medicinal products, possibly combined with medical devices. The stated objective was two-fold: both to promote their industrialization and market access, while guaranteeing a high level of health protection for patients. Since publication of the regulation, few marketing authorizations have been granted in Europe, and these have not been accompanied by commercial success. However, certain recent studies show that this is a growing sector and that France remains the leading European nation in terms of clinical trials. This round table brought together a panel of representatives of French public and private protagonists from the advanced therapy sector. The discussions focused on the conditions to ensure the success of translational research and, more generally, the French advanced therapy sector. These enabled a number of obstacles to be identified, which once lifted, by means of recommendations, would facilitate the development and success of this sector.
Collapse
Affiliation(s)
| | - Olivier Blin
- Assistance Publique - Hôpitaux de Marseille, Service de Pharmacologie, Marseille, France
| | - Jérémy Magalon
- Assistance Publique - Hôpitaux de Marseille, Laboratoire de Culture et Thérapie Cellulaire, Marseille, France - Unité Inserm 1076 : Endothélium, Pathologies Vasculaires et Cibles Thérapeutiques, Faculté de Pharmacie, Marseille, France
| | | | - Pierre Angot
- Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France
| | | | | | | | | | | | | | - Bénédicte Garbil
- Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France
| | | | - Marina Nguon
- Assistance Publique - Hôpitaux de Paris, Paris, France
| | | | | | | |
Collapse
|
4
|
Lirsac PN, Blin O, Magalon J, Angot P, de Barbeyrac E, Bilbault P, Bourg E, Damour O, Faure P, Ferry N, Garbil B, Larghero J, Nguon M, Pattou F, Thumelin S, Yates F. [Not Available]. Therapie 2015; 70:69-81. [PMID: 27393398 DOI: 10.2515/therapie/2014225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 11/24/2014] [Indexed: 11/20/2022]
Affiliation(s)
| | - Olivier Blin
- Assistance Publique-Hôpitaux de Marseille, Pharmacologie Clinique, CHU Timone, Marseille, France
| | - Jérémy Magalon
- Laboratoire de Culture et Thérapie Cellulaire, Assistance Publique des Hôpitaux de Marseille, Marseille, France; Vascular Research Center Marseille, Inserm UMRS 1076, Faculté de Pharmacie, Marseille, France.
| | | | - Pierre Angot
- Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France
| | | | | | | | | | | | | | - Bénédicte Garbil
- Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France
| | | | - Marina Nguon
- Assistance Publique-Hôpitaux de Paris, Paris, France
| | | | | | | |
Collapse
|